Benuvia Operations and PharmaCielo are partnering up to produce cGMP pharmaceutical-grade Active Pharmaceutical Ingredients for the global market, including Brazil, Australia, Europe, and the US.

PharmaCielo will be responsible for the cultivation of cannabis and hemp under Good Agricultural and Collection Practice conditions in Colombia, and Benuvia will leverage its FDA-registered and DEA-licensed (schedules I-V) cGMP development manufacturing facility in Austin, Texas, to produce final products.

"Our collaboration with PharmaCielo represents a significant milestone in our commitment to excellence in pharmaceutical development," said Darwin Richardson, CEO of Benuvia. "This partnership aligns perfectly with our mission to deliver superior quality products while adhering to the highest manufacturing standards and allows Benuvia to provide our customers with more sourcing options beyond synthetic APIs. With these additional capabilities, Benuvia and PharmaCielo customers can develop drug product formulations for their APIs for both clinical and commercial purposes."

Marc Lustig, Chairman and CEO of PharmaCielo, added, "PharmaCielo has the genetics library, expertise, and production capacity to design and deliver tailored, pharma-quality cultivars for the creation of APIs at scale. We expect this partnership with Benuvia to enable us to access additional customer opportunities while expanding our product shelf with additional cGMP final products."

For more information:
PharmaCielo
investors@pharmacielo.com
www.pharmacielo.com